Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
You may also be interested in...
The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.
Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.
Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.